Jump to content

6-Hydroxytryptamine

Add links
From Wikipedia, the free encyclopedia
6-Hydroxytryptamine
Clinical data
Other names6-Hydroxy-T; 6-HT; 6-HO-T; 6-OH-T
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • 3-(2-aminoethyl)-1H-indol-6-ol
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC10H12N2O
Molar mass176.219 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C=C1O)NC=C2CCN
  • InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-5-8(13)1-2-9(7)10/h1-2,5-6,12-13H,3-4,11H2
  • Key:WZTKTNRVJAMKAS-UHFFFAOYSA-N

6-Hydroxytryptamine (6-HT or 6-HO-T) is a serotonin receptor modulator of the tryptamine family related to serotonin.[1][2][3] It is a positional isomer of serotonin (5-hydroxytryptamine; 5-HT) and of 4-hydroxytryptamine (4-HT).[1][2][3]

Pharmacology

[edit]

6-Hydroxytryptamine shows dramatically reduced affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptors (Ki = 1,590 nM, 5,890 nM, 11,500 nM, and 5,500 nM, respectively), compared to serotonin, 4-hydroxytryptamine, 5-methoxytryptamine, and certain other tryptamines.[3] It did not produce hyperlocomotion in rodents but did partially reverse reserpine-induced hypoactivity.[4] 6-Hydroxytryptamine appears to be less susceptible to metabolism by monoamine oxidase (MAO) than serotonin.[5]

History

[edit]

6-Hydroxytryptamine was first described in the scientific literature by the 1950s.[6]

Derivatives

[edit]

Certain β-carbolines and harmala alkaloids, such as harmol, harmalol, and tetrahydroharmol, as well as their O-methyl (methoxy) analogues including harmine, harmaline, and tetrahydroharmine, are notable in being naturally occurring cyclized tryptamine derivatives of 6-hydroxytryptamine.[7][8] The same is true of certain iboga alkaloids, such as tabernanthine and ibogaline.[9][10][11][12] Tabernanthalog (DLX-007) is a synthetic simplified ibogalog analogue of tabernanthine that is under development for use as a potential pharmaceutical drug in the treatment of neuropsychiatric disorders.[13][14]

See also

[edit]

References

[edit]
  1. ^ a b Brimblecombe RW, Pinder RM (1975). "Indolealkylamines and Related Compounds". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 98–144. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M.
  2. ^ a b Hoffer A, Osmond H (1967). "Indole Hallucinogens Derived from Tryptophan". The Hallucinogens. Elsevier. pp. 443–516 (468). doi:10.1016/b978-1-4832-3296-6.50008-2. ISBN 978-1-4832-3296-6. LCCN 66030086. OCLC 332437. OL 35255701M.
  3. ^ a b c Glennon RA (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem. 30 (1): 1–12. doi:10.1021/jm00384a001. PMID 3543362. Some selected binding data are shown in Table III. N-Monomethylation and N,N-dimethylation of 5-HT decrease its affinity for 5-HT1 binding sites. Relocation of the hydroxyl group to the 4- or 6-position (ie., 4-hydroxytryptamine and 6-hydroxytryptamine, respectively) also decreases affinity (except that the affinity of 4-hydroxytryptamine is not very different from that of 5-HT for 5-HT1c sites).
  4. ^ Kalir A, Szara S (May 1966). "Synthesis and pharmacological activity of alkylated tryptamines" (PDF). J Med Chem. 9 (3): 341–344. doi:10.1021/jm00321a017. PMID 5960901.
  5. ^ Erspamer V, Ferrini R, Glasser A (December 1960). "A note on the oxidative deamination of isomers of 5-hydroxytryptamine and other indolealkylamines". J Pharm Pharmacol. 12: 761–764. doi:10.1111/j.2042-7158.1960.tb12743.x. PMID 13697284.
  6. ^ Vane JR (March 1959). "The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation". Br J Pharmacol Chemother. 14 (1): 87–98. doi:10.1111/j.1476-5381.1959.tb00933.x. PMC 1481817. PMID 13651584.
  7. ^ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  8. ^ Grella B, Dukat M, Young R, Teitler M, Herrick-Davis K, Gauthier CB, Glennon RA (April 1998). "Investigation of hallucinogenic and related beta-carbolines". Drug Alcohol Depend. 50 (2): 99–107. doi:10.1016/s0376-8716(97)00163-4. PMID 9649961.
  9. ^ Popik, Piotr; Skolnick, Phil (1999). "Pharmacology of Ibogaine and Ibogaine-Related Alkaloids". The Alkaloids: Chemistry and Biology. Vol. 52. Elsevier. p. 197–231. doi:10.1016/s0099-9598(08)60027-9. ISBN 978-0-12-469552-8. Retrieved 17 June 2025.
  10. ^ Lavaud C, Massiot G (2017). "The Iboga Alkaloids" (PDF). Prog Chem Org Nat Prod. 105: 89–136. doi:10.1007/978-3-319-49712-9_2. PMID 28194562.
  11. ^ Iyer RN, Favela D, Zhang G, Olson DE (March 2021). "The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs". Nat Prod Rep. 38 (2): 307–329. doi:10.1039/d0np00033g. PMC 7882011. PMID 32794540.
  12. ^ Hughes, Alexander J.; Hamelink, Charles R.; Townsend, Steven D. (5 September 2024). "Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids". European Journal of Organic Chemistry. doi:10.1002/ejoc.202400432. ISSN 1434-193X.
  13. ^ Chen MJ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, Phan L, Johnson D, McIntyre RS, Rosenblat JD (July 2025). "Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review". Psychiatry Res. 349: 116532. doi:10.1016/j.psychres.2025.116532. PMID 40354769.
  14. ^ Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=6-Hydroxytryptamine&oldid=1296125901"